1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA A Cancer J Clinicians,2024,74(3):229-263. 2 Asselain B,Barlow W,Bartlett J,et al.Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:meta-analysis of individual patient data from ten randomised trials[J].Lancet Oncol,2018,19(1):27-39. 3 Spring LM,Fell G,Arfe A,et al.Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival:a comprehensive meta-analysis[J].Clin Cancer Res,2020,26(12):2838-2848. 4 Cortazar P,Zhang L,Untch M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J].Lancet,2014,384(9938):164-172. 5 Panet F,Papakonstantinou A,Borrell M,et al.Use of ctDNA in early breast cancer:analytical validity and clinical potential[J].NPJ Breast Cancer,2024,10(1):50. 6 Dowling GP,Daly GR,Hegarty A,et al.Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer:meta-analysis[J].Br J Surg,2024,111(5):znae132. 7 Prasetiyo PD,Baskoro BA,Hariyanto TI.The role of nutrition-based index in predicting survival of breast cancer patients:a systematic review and meta-analysis[J].Heliyon,2024,10(1):e23541. 8 Dobiášová M,Frohlich J.The plasma parameter log(TG/HDL-C)as an atherogenic index:correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma(FERHDL)[J].Clin.Biochem,2001,34(7):583-588. 9 Liu Z,Zhang L,Wang L,et al.The predictive value of cumulative atherogenic index of plasma(AIP)for cardiovascular outcomes:a prospective community-based cohort study[J].Cardiovasc Diabetol,2024,23:264. 10 Han M,Wang H,Yang S,et al.Triglyceride glucose index and atherogenic index of plasma for predicting colorectal neoplasms in patients without cardiovascular diseases[J].Front Oncol,2022,12:1031259. 11 Tagoe EA,Dwamena-Akoto E,Nsaful J,et al.High atherogenic index of plasma and cardiovascular risk factors among ghanaian breast cancer patients[J].Exp Biol Med,2020,245(18):1648-1655. 12 Izuegbuna OO,Olawumi HO,Agodirin OS,et al.Lipid profile and atherogenic risk assessment in nigerian breast cancer patients-a cross-sectional study[J].J Am Nutr Assoc,2024,43(7):582-591. 13 滕熠,张晓丹,夏昌发,等.中国与全球癌症发病、死亡和患病对比及其预测分析:GLOBOCAN 2022数据解读[J].中华肿瘤防治杂志,2024,31(23):1413-1420. 14 Lee K,Kruper L,Dieli-Conwright CM,et al.The Impact of obesity on breast cancer diagnosis and treatment[J].Curr Oncol Rep,2019,21(5):41. 15 Nouri M,Mohsenpour MA,Katsiki N,et al.Effect of serum lipid profile on the risk of breast cancer:Systematic review and meta-analysis of 1,628,871 women[J].J Clin Med,2022,11(15):4503. 16 Nam JS,Kim MK,Nam JY,et al.Association between atherogenic index of plasma and coronary artery calcification progression in Korean adults[J].Lipids Health Dis,2020,19(1):157. 17 Zhu XW,Deng FY,Lei SF.Meta-analysis of atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus[J].Primary Care Diabetes,2015,9(1):60-67. 18 Assempoor R,Daneshvar MS,Taghvaei A,et al.Atherogenic index of plasma and coronary artery disease:a systematic review and meta-analysis of observational studies[J].Cardiovasc Diabetol,2025,24(1):35. 19 Qi L,Kang N,Chen X,et al.Predictive value of plasma atherogenic index for microalbuminuria in newly diagnosed patients with type 2 diabetes mellitus[J].Diab Metab Syndr Obes,2022,Volume 15:1245-1252. 20 Karabay E,Karsiyakali N,Duvar S,et al.Relationship between plasma atherogenic index and final pathology of bosniak III-IV renal masses:a retrospective,single-center study[J].BMC Urol,2019,19(1):85. 21 Yang MH,Rampal S,Sung J,et al.The association of serum lipids with colorectal adenomas[J].Am J Gastroenterol,2013,108(5):833-841. 22 Melvin JC,Seth D,Holmberg L,et al.Lipid profiles and risk of breast and ovarian cancer in the swedish AMORIS study[J].Cancer Epidemiol Biomarkers Prev,2012,21(8):1381-1384. 23 De Nardo D,Labzin LI,Kono H,et al.High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3[J].Nat Immunol,2014,15(2):152-160. 24 Klemm S,Zimmermann S,Peschel C,et al.Bcl10 and malt1 control lysophosphatidic acid-induced NF-κB activation and cytokine production[J].Proc Natl Acad Sci U S A,2007,104(1):134-138. 25 Bureau F,Vanderplasschen A,Jaspar F,et al.Constitutive nuclear factor-κB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins[J].Blood,2002,99(10):3683-3691. 26 Dai D,Chen B,Wang B,et al.Pretreatment TG/HDL-C ratio is superior to triacylglycerol level as an independent prognostic factor for the survival of triple negative breast cancer patients[J].J Cancer,2016,7(12):1747-1754. 27 Marvalim C,Datta A,Lee SC.Role of p53 in breast cancer progression:an insight into p53 targeted therapy[J].Theranostics,2023,13(4):1421-1442. 28 Fei F,Zhang K,Siegal GP,et al.A simplified breast cancer prognostic score:comparison with the AJCC clinical prognostic staging system[J].Mod Pathol,2021,34(12):2141-2147. 29 张雯娟,孙鹏飞,聂芬,等.新辅助化疗对乳腺癌患者血脂影响及因素分析[J].中华普通外科学文献(电子版),2019,13(1):25-29. |